Abbott Laboratories vs Stryker
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Abbott Laboratories and Stryker side by side, using each one’s latest annual report. Here is what stands out:
- Abbott Laboratories is the larger business, with $44.3B of revenue in fiscal 2025 against $25.1B for Stryker, about 1.8 times as much.
- Stryker grew revenue faster (11.2%, against 5.7%).
- Stryker kept more of each dollar of sales as operating profit (19.5% operating margin, against 18.2%).
- Investors pay more for each dollar of Stryker’s earnings: a P/E of 31.7x against 29.3x for Abbott Laboratories.
Who comes out ahead
Of the 11 measures where higher (or lower) is clearly better, how many each company leads.
Abbott Laboratories
ABT
3/11
Net marginNet debt / EBITDAShare count change
Stryker
SYK
7/11
Revenue growth5-year growthGross marginOperating marginFCF marginReturn on capitalReturn on equity
Side by side
Best in the row
| Latest fiscal year | ABT FY25 | SYK FY25 |
|---|---|---|
| Size | ||
| Market cap | $183.2B | $118.2B |
| Revenue | $44.3B | $25.1B |
| Free cash flow | $7.4B | $4.3B |
| Net income | $6.5B | $3.2B |
| Growth | ||
| Revenue growth | 5.7% | 11.2% |
| 5-year growth | 5.1% | 11.8% |
| Share count change | 0.0% | 0.2% |
| Profitability | ||
| Gross margin | 56.4% | 64.0% |
| Operating margin | 18.2% | 19.5% |
| Net margin | 14.7% | 12.9% |
| FCF margin | 16.7% | 17.1% |
| Return on capital | 11.2% | 11.3% |
| Return on equity | 13.1% | 15.1% |
| Balance sheet | ||
| Net debt | $4.0B | $10.8B |
| Net debt / EBITDA | 0.4x | 1.7x |
| Dividends and buybacks | $5.0B | $1.3B |
| Valuation & quality | ||
| P/E | 29.3x | 31.7x |
| Piotroski F-score | 6 | 6 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.